| 摘要 |
2049318 9112261 PCTABS00006 The present invention concerns steroidic 5.alpha.-reductase inhibitors having formula (I) wherein R1 is hydrogen, a C1-C6 alkyl group, an aryl-C1-C6alkyl group, or an aroyl group; Y is oxygen or sulphur; W is a group (2) wherein each of R2 and R3 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C5-C6 cycloalkyl, C6-C9 cycloalkylalkyl and aryl, wherein each of the groups alkyl, cycloalkyl, cycloalkylalkyl and aryl may be unsubstituted or substituted by a substituent -OR4 wherein R4 is hydrogen or C1-C4 alkyl; A is hydrogen, C1-C6 alkyl, C5-C6 cycloalkyl or C6-C9 cycloalkylalkyl wherein each of the groups alkyl, cycloalkyl and cycloalkylalkyl, may be unsubstituted or substituted by a substituent chosen from: a) -OR4 wherein R4 is as defined above, and b) (3) wherein either each of R5 and R6 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C5-C6 cycloalkyl and aryl, or R5 and R6, taken together with the nitrogen atom to which they are linked, form a pentatomic or hexatomic saturated heteromonocyclic ring, optionally containing at least one additional heteroatom selected from oxygen and nitrogen; and the symbol (----) represents a single or a double bond, and pharmaceutical acceptable salts thereof. In view of their 5.alpha.-reductase inhibiting activity the compounds of the invention can be useful for the treatment of androgen dependent conditions.
|
